Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder
Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder
复制标题
DOI：
10.1016/j.jsat.2019.06.007
复制
发表时间：
2019-09-01
影响因子：
3.9
通讯作者：
Strang, John
中科院分区：
文献类型：
--
作者：
Tompkins, Charlotte N. E.;Neale, Joanne;Strang, John
目的：丁丙诺啡的缓释植入式和贮库注射制剂是阿片类药物使用障碍治疗中的最新进展。这样的制剂消除了每日给药的需要，并在数周或数月的时间内为患者提供持续浓度的丁丙诺啡。我们探讨了阿片类药物使用者接受缓释丁丙诺啡贮库注射的个人意愿和影响其interest.Methods的因素：该研究于2018年在伦敦进行，当时贮库丁丙诺啡被许可在欧洲使用。对以下人员进行了36次面对面的半结构化定性访谈：i）每天使用海洛因且未接受任何阿片类药物使用治疗（n = 12）;或ii）每日口服丁丙诺啡（n = 12）;或iii）每日口服美沙酮（n = 12）。参与者被问及他们是否愿意接受丁丙诺啡，并被鼓励讨论可能改变他们观点的因素。访谈数据进行了分析迭代Categorization.Findings的阶段：参与者表示愿意接受贮库丁丙诺啡的高水平。他们的观点受到长效丁丙诺啡六个关键特征的积极和消极影响：i）减少与药房和药物治疗服务的接触; ii）对非法药物使用和恢复的影响; iii）长效丁丙诺啡的感知有效性; iv）长效丁丙诺啡注射剂的持续时间和剂量; v）长效丁丙诺啡注射剂的临床给药;和vi）与贮库丁丙诺啡注射剂相关的潜在副作用。结论：接受给定药物的意愿是复杂的、个体的和可变的。类阿片使用者似乎可能欢迎在类阿片激动剂药物方面有更多的选择和灵活性，并且似乎更有可能接受和坚持使用长效丁丙诺啡，如果它能够使他们减少非法药物使用并促进他们康复的话。现在需要研究来评估患者报告的接受储库丁丙诺啡的意愿是否转化为实际的吸收和依从性。
Aims: Prolonged-release implantable and depot injection formulations of buprenorphine are very recent developments in the treatment of opioid use disorder. Such formulations remove the need for daily dosing and provide patients with sustained concentrations of buprenorphine over a period of weeks or months. We explored opioid users' personal willingness to receive prolonged-release buprenorphine depot injections and factors influencing their interest.Methods: The study took place in London during 2018, before depot buprenorphine was licensed for use in Europe. Thirty-six face-to-face, semi-structured qualitative interviews were conducted with people who were: i) using heroin daily and not receiving any treatment for opioid use (n = 12); or ii) prescribed daily oral buprenorphine (n = 12); or iii) prescribed daily oral methadone (n = 12). Participants were asked about their willingness to receive depot buprenorphine and were encouraged to discuss factors that might alter their opinions. Interview data were analysed following the stages of Iterative Categorization.Findings: Participants expressed a high level of willingness to receive depot buprenorphine. Their views were influenced both positively and negatively by six key features of depot buprenorphine: i) reduced contact with pharmacies and drug treatment services; ii) impact on illicit drug use and recovery; iii) the perceived effectiveness of depot buprenorphine; iv) the duration and dosage of depot buprenorphine injections; v) clinical administration of the depot buprenorphine injection; and vi) potential for side effects associated with the depot buprenorphine injection.Conclusions: Willingness to receive a given medication is complex, individual and changeable. Opioid users seem likely to welcome greater choice and flexibility in respect of opioid agonist medications and appear more likely to accept and adhere to depot buprenorphine if it enables them to reduce their illicit drug use and facilitates their recovery. Research is now needed to assess whether patients' reported willingness to receive depot buprenorphine translates into actual uptake and adherence.